We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Apogee's (APOG) Earnings Miss Estimates in Q1, Down Y/Y
Read MoreHide Full Article
Apogee Enterprises, Inc. (APOG - Free Report) reported first-quarter fiscal 2021 (ended May 30, 2020) adjusted earnings per share of 15 cents, missing the Zacks Consensus Estimate of 34 cents. Also, the reported figure plummeted 74% from the prior-year quarter.
Including one-time items, the company reported earnings per share of 11 cents compared with the 58 cents recorded in the year-ago quarter.
Apogee reported revenues of $289 million during the quarter, marking a year-over-year decline of 18.6% on lower volumes across all of the company’s segments on account of the coronavirus crisis.
Operational Update
Cost of sales in the fiscal first quarter was down 17% year over year to $229 million. Gross profit declined 26% year over year to $60 million. Gross margin came in at 21% compared with the year-earlier quarter’s 23%.
Selling, general and administrative (SG&A) expenses decreased 7% year over year to $54 million. Adjusted operating income slumped 65% year over year to $8 million. Operating margin in the reported quarter was 3% compared with the prior-year quarter’s 6%.
Apogee Enterprises, Inc. Price, Consensus and EPS Surprise
In the fiscal first quarter, revenues in the Architectural Framing Systems segment slid 17% year over year to $150 million on dismal lower volume due to several COVID-19-related project delays and disruptions. The segment’s operating income plunged 41% year over year to around $7 million.
Revenues in the Architectural Glass Systems segment dropped 23% year over year to $77 million, reflecting lower volumes due to coronavirus outbreak. The segment reported an operating loss of $0.5 million as against the operating profit of $6.4 million registered in the prior-year quarter. This decline resulted from lower volume and the coronavirus pandemic-related costs.
Revenues in the Architectural Services segment slipped 2% year over year to $64 million on project delays due to the pandemic. The segment’s operating profit increased 17% year over year to $5.3 million. This was driven by strong project execution and effective cost management.
Revenues in the Large-Scale Optical Technologies segment tanked 70% year over year to $6 million as most of the segment’s customers were closed for a large part of the quarter. In response to the lower demand, and to comply with state government mandates, the segment closed its two primary manufacturing locations for most of the fiscal first quarter. These facilities are expected to resume operations late in the fiscal second quarter, as customers reopen. The segment incurred an operating loss of $3 million as against the prior-year quarter’s operating profit of $4 million, reflecting lower volume.
Backlog
The Architectural Services segment’s backlog rose 42% year over year to a record $685 million in the reported quarter. Backlog in the Architectural Framing segment amounted to $423 million, down 2% from the prior quarter’s $432 million.
Financial Position
Apogee had cash and cash equivalents of $12 million at the end of fiscal first quarter compared with the $29 million witnessed at the end of prior-year quarter. Cash generated from operating activities were $24 million in the reported quarter compared with cash utilization of around $10 million in the prior-year quarter. Long-term debt was $56 million as of May 30, 2020 compared with $213 million as of Feb 29, 2020.
In fiscal first quarter, Apogee returned $4.9 million of cash to shareholders through dividend payments and repurchased 231,000 shares for $4.7 million before announcing the temporary suspension of its share-repurchase program.
Fiscal 2021 Guidance
The company expects to report solid results in the upcoming quarters with the stabilization in its end markets as well as in the economy. Apogee’s Large-Scale Optical customers have started to gradually reopen, while Architectural segments expect moderate project delays. The company is also poised to gain from strong backlog. Apart from this, the company expects to benefit from cost-reduction actions in the fiscal second quarter. However, given the coronavirus pandemic-related uncertainties in the end markets and economy, the company has not issued any guidance for fiscal 2021.
Price Performance
Shares of the company have depreciated 52.1% in the past year compared with the industry’s decline of 55.1%.
Zacks Rank & Stocks to Consider
Apogee currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Industrial Products sector are Lakeland Industries, Inc. (LAKE - Free Report) , Broadwind Energy, Inc. (BWEN - Free Report) and Axon Enterprise, Inc. . While Lakeland Industries sports a Zacks Rank #1 (Strong Buy), Broadwind Energy and Axon carry a Zacks Rank of 2 (Buy), at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Lakeland Industries has a projected earnings growth rate of 127.8% for fiscal 2020. The company’s shares have appreciated 44.1% in the past three months.
Broadwind Energy has an expected earnings growth rate of 174% for the current year. The stock has appreciated 6% over the past three months.
Axon has an estimated earnings growth rate of 14.4% for the ongoing year. The company’s shares have rallied 21.3% in the past three months.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Apogee's (APOG) Earnings Miss Estimates in Q1, Down Y/Y
Apogee Enterprises, Inc. (APOG - Free Report) reported first-quarter fiscal 2021 (ended May 30, 2020) adjusted earnings per share of 15 cents, missing the Zacks Consensus Estimate of 34 cents. Also, the reported figure plummeted 74% from the prior-year quarter.
Including one-time items, the company reported earnings per share of 11 cents compared with the 58 cents recorded in the year-ago quarter.
Apogee reported revenues of $289 million during the quarter, marking a year-over-year decline of 18.6% on lower volumes across all of the company’s segments on account of the coronavirus crisis.
Operational Update
Cost of sales in the fiscal first quarter was down 17% year over year to $229 million. Gross profit declined 26% year over year to $60 million. Gross margin came in at 21% compared with the year-earlier quarter’s 23%.
Selling, general and administrative (SG&A) expenses decreased 7% year over year to $54 million. Adjusted operating income slumped 65% year over year to $8 million. Operating margin in the reported quarter was 3% compared with the prior-year quarter’s 6%.
Apogee Enterprises, Inc. Price, Consensus and EPS Surprise
Apogee Enterprises, Inc. price-consensus-eps-surprise-chart | Apogee Enterprises, Inc. Quote
Segment Performance
In the fiscal first quarter, revenues in the Architectural Framing Systems segment slid 17% year over year to $150 million on dismal lower volume due to several COVID-19-related project delays and disruptions. The segment’s operating income plunged 41% year over year to around $7 million.
Revenues in the Architectural Glass Systems segment dropped 23% year over year to $77 million, reflecting lower volumes due to coronavirus outbreak. The segment reported an operating loss of $0.5 million as against the operating profit of $6.4 million registered in the prior-year quarter. This decline resulted from lower volume and the coronavirus pandemic-related costs.
Revenues in the Architectural Services segment slipped 2% year over year to $64 million on project delays due to the pandemic. The segment’s operating profit increased 17% year over year to $5.3 million. This was driven by strong project execution and effective cost management.
Revenues in the Large-Scale Optical Technologies segment tanked 70% year over year to $6 million as most of the segment’s customers were closed for a large part of the quarter. In response to the lower demand, and to comply with state government mandates, the segment closed its two primary manufacturing locations for most of the fiscal first quarter. These facilities are expected to resume operations late in the fiscal second quarter, as customers reopen. The segment incurred an operating loss of $3 million as against the prior-year quarter’s operating profit of $4 million, reflecting lower volume.
Backlog
The Architectural Services segment’s backlog rose 42% year over year to a record $685 million in the reported quarter. Backlog in the Architectural Framing segment amounted to $423 million, down 2% from the prior quarter’s $432 million.
Financial Position
Apogee had cash and cash equivalents of $12 million at the end of fiscal first quarter compared with the $29 million witnessed at the end of prior-year quarter. Cash generated from operating activities were $24 million in the reported quarter compared with cash utilization of around $10 million in the prior-year quarter. Long-term debt was $56 million as of May 30, 2020 compared with $213 million as of Feb 29, 2020.
In fiscal first quarter, Apogee returned $4.9 million of cash to shareholders through dividend payments and repurchased 231,000 shares for $4.7 million before announcing the temporary suspension of its share-repurchase program.
Fiscal 2021 Guidance
The company expects to report solid results in the upcoming quarters with the stabilization in its end markets as well as in the economy. Apogee’s Large-Scale Optical customers have started to gradually reopen, while Architectural segments expect moderate project delays. The company is also poised to gain from strong backlog. Apart from this, the company expects to benefit from cost-reduction actions in the fiscal second quarter. However, given the coronavirus pandemic-related uncertainties in the end markets and economy, the company has not issued any guidance for fiscal 2021.
Price Performance
Shares of the company have depreciated 52.1% in the past year compared with the industry’s decline of 55.1%.
Zacks Rank & Stocks to Consider
Apogee currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Industrial Products sector are Lakeland Industries, Inc. (LAKE - Free Report) , Broadwind Energy, Inc. (BWEN - Free Report) and Axon Enterprise, Inc. . While Lakeland Industries sports a Zacks Rank #1 (Strong Buy), Broadwind Energy and Axon carry a Zacks Rank of 2 (Buy), at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Lakeland Industries has a projected earnings growth rate of 127.8% for fiscal 2020. The company’s shares have appreciated 44.1% in the past three months.
Broadwind Energy has an expected earnings growth rate of 174% for the current year. The stock has appreciated 6% over the past three months.
Axon has an estimated earnings growth rate of 14.4% for the ongoing year. The company’s shares have rallied 21.3% in the past three months.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>